Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: a study in patients with type 2 diabetes and controls.

Valdivielso P, Puerta S, Rioja J, Alonso I, Ariza MJ, Sánchez-Chaparro MA, Palacios R, González-Santos P.

Clin Chim Acta. 2010 Mar;411(5-6):433-7. doi: 10.1016/j.cca.2009.12.022. Epub 2010 Jan 6.

PMID:
20059992
2.

Fasting apolipoprotein B48 is a marker for peripheral arterial disease in type 2 diabetes.

Mancera-Romero J, Sánchez-Chaparro MA, Rioja J, Ariza MJ, Olivecrona G, González-Santos P, Valdivielso P.

Acta Diabetol. 2013 Jun;50(3):383-9. doi: 10.1007/s00592-012-0434-x. Epub 2012 Oct 9.

PMID:
23053881
3.

The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes.

Taggart C, Gibney J, Owens D, Collins P, Johnson A, Tomkin GH.

Diabet Med. 1997 Dec;14(12):1051-8.

PMID:
9455933
4.
5.

Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?

Battula SB, Fitzsimons O, Moreno S, Owens D, Collins P, Johnson A, Tomkin GH.

Metabolism. 2000 Aug;49(8):1049-54.

PMID:
10954025
6.

Increased serum apolipoprotein B48 concentration in patients with metabolic syndrome.

Kinoshita M, Ohnishi H, Maeda T, Yoshimura N, Takeoka Y, Yasuda D, Kusano J, Mashimo Y, Saito S, Shimamoto K, Teramoto T.

J Atheroscler Thromb. 2009 Aug;16(4):517-22. Epub 2009 Aug 27.

7.

Significant increase of apolipoprotein B48 levels by a standard test meal in type 2 diabetic patients with nephropathy.

Yamamoto T, Hirano T, Mori Y, Tokuno A, Nagashima M, Takada M, Morita R, Lee S, Hayashi T, Adachi M.

J Atheroscler Thromb. 2008 Aug;15(4):199-205.

8.

Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state.

Smith D, Watts GF, Dane-Stewart C, Mamo JC.

Eur J Clin Invest. 1999 Mar;29(3):204-9.

PMID:
10202376
9.

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-Santos P.

Cardiovasc Diabetol. 2009 Jan 8;8:1. doi: 10.1186/1475-2840-8-1.

10.

Fasting apolipoprotein B48 is associated with asymptomatic peripheral arterial disease in type 2 diabetic subjects: a case-control study.

Lapice E, Cipriano P, Patti L, Romano G, Vaccaro O, Rivellese AA.

Atherosclerosis. 2012 Aug;223(2):504-6. doi: 10.1016/j.atherosclerosis.2012.05.038. Epub 2012 Jun 13.

PMID:
22762727
11.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
12.

Factors influencing elevated serum apolipoprotein B48 in diabetic and control participants.

Leonard A, Tun TK, Gaffney R, Sharma J, Gibney J, Boran G.

Br J Biomed Sci. 2014;71(4):145-50.

PMID:
25562991
13.

Meal testing and postprandial state of type 2 diabetic patients with metabolic syndrome.

Brădescu OM, Georgescu M, Ifrim S, Ioacără S, Ionescu-Tîrgovişte C.

Rom J Intern Med. 2005;43(1-2):97-113.

PMID:
16739870
14.

Postprandial hyperlipidemia after a fat loading test in minority adolescents with type 2 diabetes mellitus and obesity.

Umpaichitra V, Banerji MA, Castells S.

J Pediatr Endocrinol Metab. 2004 Jun;17(6):853-64.

PMID:
15270403
15.

Apo E genotype, diabetes, and peripheral arterial disease in older men: the Honolulu Asia-aging study.

Resnick HE, Rodriguez B, Havlik R, Ferrucci L, Foley D, Curb JD, Harris TB.

Genet Epidemiol. 2000 Jul;19(1):52-63.

PMID:
10861896
16.

Impaired postprandial metabolism of apolipoprotein B48-containing remnant particles in normolipidemic subjects with brittle type 1 diabetes.

Su JW, Lambert JE, Clandinin MT, Proctor SD.

Diabetes Care. 2009 Feb;32(2):e21. doi: 10.2337/dc08-1573. No abstract available.

PMID:
19171731
18.

Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidemia in diabetes.

Phillips C, Bennett A, Anderton K, Owens D, Collins P, White D, Tomkin GH.

Metabolism. 2002 Jul;51(7):847-52.

PMID:
12077729
20.

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR.

Diabetologia. 2006 Sep;49(9):2049-57. Epub 2006 Jul 1.

PMID:
16816950

Supplemental Content

Support Center